Stock MRUS MERUS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News Merus N.V.

Equities

MRUS

NL0011606264

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
45.85 USD +2.99% Intraday chart for Merus N.V. -3.15% +66.73%
May. 13 Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab MT
May. 13 Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab
MT
Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation
DJ
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
GL
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
AQ
Earnings Flash (MRUS) MERUS N.V. Posts Q1 Revenue $7.9M
MT
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GL
Merus N.V. Appoints Jason Haddock as Non-Executive Director
CI
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
GL
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
GL
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says
MT
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
GL
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
AQ
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
GL
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target
MT
Needham Raises Price Target on Merus to $66 From $65, Maintains Buy Rating
MT
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies
MT
Gilead, Merus to Collaborate on Trispecific Antibody Research
DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
CI
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRUS Stock
  4. News Merus N.V.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW